<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906070</url>
  </required_header>
  <id_info>
    <org_study_id>HB-AT-001</org_study_id>
    <nct_id>NCT04906070</nct_id>
  </id_info>
  <brief_title>Radiation Therapy (HB-001) by Alpha-particle Sources for Recurrent Malignant Solid Tumors in Japan</brief_title>
  <official_title>Study of the Safety and Efficacy of Radiation Therapy (HB-001) by Alpha-particle Sources for Recurrent Malignant Solid Tumors in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hekabio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hekabio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An intratumoral alpha particle based approach for cancer treatment using diffusion&#xD;
      alpha-emitting radiation therapy (DaRT)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, open label, single arm, controlled study, assessing the safety&#xD;
      and efficacy of diffusing alpha emitters radiation therapy (DaRT) delivered through&#xD;
      radioactive seeds inserted into the tumor. This approach combines the advantages of local&#xD;
      intratumoral irradiation of the tumor, as used in conventional brachytherapy, with the power&#xD;
      of the alpha radiation emitting atoms, that will be introduced in quantities considerably&#xD;
      lower than radiation therapy already used in patients. Superficial lesions with&#xD;
      histopathological confirmation of malignancy will be treated using DaRT seeds. Reduction in&#xD;
      tumor size 70 days after DaRT insertion will be assessed. Safety will be assessed by the&#xD;
      incidence, severity and frequency of all Adverse Events (AE).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response to HB-001</measure>
    <time_frame>9 - 11 weeks after HB-001 seed insertion</time_frame>
    <description>Assessment of tumors response using the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 weeks after HB-001 insertion</time_frame>
    <description>The incidence, frequency, severity and causality of adverse events related to the HB-001</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>HB-001 DaRT Seeds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HB-001</intervention_name>
    <description>An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.</description>
    <arm_group_label>HB-001 DaRT Seeds</arm_group_label>
    <other_name>DaRT(Diffusing Alpha Radiation Emitters Therapy)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Head and neck cancer or breast cancer patients with histopathological proven&#xD;
             malignancies who have a history of radiation therapy and who have been diagnosed with&#xD;
             refractory malignancies with or without medical treatment.&#xD;
&#xD;
          2. Tumor size is 5 cm or less in the longest diameter&#xD;
&#xD;
          3. Age 18 years or older&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group performance status is 2 or less&#xD;
&#xD;
          5. Life expectancy: 6 months or longer&#xD;
&#xD;
          6. Vital signs (systolic and diastolic blood pressure, pulse rate, body temperature, and&#xD;
             respiratory rate) are stable&#xD;
&#xD;
          7. Platelet count &gt;= 100,000/mm3 and prothrombin time Prothrombin Time-International&#xD;
             Normalized Ratio &lt;= 1.8&#xD;
&#xD;
          8. Women of childbearing potential have to be confirmed not pregnant by a pregnancy test&#xD;
             and have to agree to prevent conception throughout the study.&#xD;
&#xD;
          9. Having received explanation about the study, consented to participate in the study and&#xD;
             signed the informed consent form.&#xD;
&#xD;
         10. Measurable disease according to RECIST v1.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The size of the tumor more than 5 cm in the maximum diameter.&#xD;
&#xD;
          2. ECOG performance status is 3 or higher&#xD;
&#xD;
          3. Continuously receiving medication that may have a significant impact on the evaluation&#xD;
             of safety or efficacy, such as immunosuppressants and/or corticosteroids.&#xD;
&#xD;
          4. History of serious allergy to the medicine for the treatments like anesthesia.&#xD;
&#xD;
          5. There are tumors to be preferentially treated such as metastatic lesion other than the&#xD;
             target tumor&#xD;
&#xD;
          6. Having received chemotherapeutic drugs (except hormonal agents), immunotherapeutic&#xD;
             agents, and molecular targeting agents in the past 30 days, which may affect the&#xD;
             assessment of the safety or efficacy of the HB-001 brachytherapy.&#xD;
&#xD;
          7. Having received immune checkpoint inhibitor in the past 2 months, which may affect the&#xD;
             assessment of the safety or efficacy of the HB-001 brachytherapy.&#xD;
&#xD;
          8. Having participated in different clinical studies in the past 30 days, which may&#xD;
             affect the assessment of the safety or efficacy of HB-001 brachytherapy&#xD;
&#xD;
          9. Pregnant women or breast-feeding mothers&#xD;
&#xD;
         10. Those who do not wish to sign the informed consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshiro Mabuchi</last_name>
    <role>Study Director</role>
    <affiliation>Hekabio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toshiro Mabuchi</last_name>
    <phone>+81-3-6205-7585</phone>
    <email>toshiro.mabuchi@hekabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Miyagi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rei Umezawa, M.D., Ph.D.</last_name>
      <phone>+81-22-717-7000</phone>
    </contact>
    <investigator>
      <last_name>Rei Umezawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satoaki Nakamura, M.D., Ph.D.</last_name>
      <phone>+81-72-804-0101</phone>
    </contact>
    <investigator>
      <last_name>Satoaki Nakamura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshi Igaki, M.D., Ph.D.</last_name>
      <phone>+81-3-3542-2511</phone>
    </contact>
    <investigator>
      <last_name>Hiroshi Igaki, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical And Dental University Medical Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuma Toda, M.D., Ph.D.</last_name>
      <phone>+81-3-3813-6111</phone>
    </contact>
    <investigator>
      <last_name>Kazuma Toda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

